Trophogen, Inc. Awarded $756,000 for Second Year of Phase 2 NIH/NCI Fast Track SBIR Grant for Development of Novel Human VEGF Analogs for Targeted Imaging of Undifferentiated Thyroid Cancer.
ROCKVILLE, MD, July 7th, 2015
Trophogen, Inc. Announces Signing of Exclusive Global Veterinary License and Purchase Agreement With Zoetis, Inc. for Recombinant Long- Acting and Superactive Bovine Follicle- Stimulating Hormone (rbFSH) Analog for Superovulation in Cows.
ROCKVILLE, MD, June 2nd, 2015
Trophogen Inc. and Bioniche Life Sciences Inc. terminated exclusive global veterinary
license agreement effective immediately.
ROCKVILLE, MD, January 30, 2013
Bioniche Presents Preliminary Data on the Use of In-Licensed
Superagonist Hormone Technology in Cattle.
Data presented at the International Congress on Animal Reproduction in Vancouver, B.C.
BELLEVILLE, ON, July 31, 2012
Trophogen Selects ABL as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog.
ROCKVILLE, MD, January 10, 2012
Bioniche & Trophogen Sign Exclusive Global Veterinary License Agreement for Superagonist Hormone Technology Platform
BELLEVILLE, ON and ROCKVILLE, MD, June 23, 2010
Banking on a Big Biobetters Bonanza: Will China Use its Capabilities to Create Improved Biologics?
CPB Review., 2012
Trophogen wants to score $10M, development deals..
Washington Business Journal., March 23, 2007
The importance of sharing.
Baltimore Business Journal., April
Events & Networking.
The Business Gazette., February 2006
Adventure With Ventures.
The Scientist, February 2006
The Gazette, February 2005
Breaking with academia a tough choice for scientists.
The Daily Record, March 2002
Local biotech pulls NIH license away from giant pharma.
Washington Business Journal,, March 2002
(99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.
Thyroid., Vol.24(8), 2014.
Thyrotropic activity of recombinant human glycoprotein hormone analogs and pituitary mammalian gonadotropins in goldfish
(Carassius auratus): insights into the evolution of thyrotropin receptor specificity.
Gen Comp Endocrinol, Vol.177(1), 2012.
Identification of novel TSH interaction sites by systematic binding analysis of the TSHR hinge region.
Endocrinology, Vol.152(8), 2011.
Effects of recombinant human thyroid-stimulating hormone superagonists on thyroidal uptake of 18F-fluorodeoxyglucose and radioiodide.
Thyroid, Vol.21(7), 2011.
Induction of increased FDG uptake and loss of sodium-iodide symporter expression by VEGFR-2 inhibitor in FRTL-5 cells:
An in vitro flip-flop mechanizm.
Nuklear Medizin, Leipzig Vol.54, 2010.
Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras.
J Nucl Med, Vol.50(8), 2009.
Opportunities for the production of reccombinant gonadotropins for assisted reproduction and emnbryo transfer.
Canadian and American Embryo Transfer Association Joint Convention Proceedings, 59-67, 2009.
The superagonistic activity of bovine thyroid-stimulating hormone (TSH) and the human TR1401 TSH analog is
determined by specific amino acids in the hinge region of the human TSH receptor.
J Biol Chem, Vol.284(24), 2009.
Challenges and opportunities of trapping ligands.
Mol Pharmacol, Vol.72(2), 2007.
Thyroid-Stimulating Hormone and Thyroid-Stimulating
Hormone Receptor Structure-Function Relationships.
Physiol Rev, Vol.82, 2002.
Bioengineering of Human Thyrotropin Superactive Analogs by
Site-directed “Lysine-scanning” Mutagenesis
JBC, Vol.275, 2000.
A rational design strategy for protein hormone superagonists.
Nature Biotechnology,Vol 16, September 1998.
Novel Insights into the Molecular Mechanisms of Human Thyrotropin Action: Structural, Physiological, and
Therapeutic Implications for the Glycoprotein Hormone Family.
Endocrine Reviews, Vol.18, August 1997.
Engineering human glycoprotein hormone superactive analogues.
Nature Biotechnology, Vol.14, October 1996.